Cargando…
Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
OBJECTIVE: Mycophenolate mofetil (MMF) is an established therapy for systemic sclerosis (SSc), but its pharmacokinetics in this disease remains unexplored. We have investigated drug exposure in MMF-treated patients with SSc in relation to clinical features of the disease and common concomitant drugs...
Autores principales: | Andréasson, Kristofer, Neringer, Karl, Wuttge, Dirk M., Henrohn, Dan, Marsal, Jan, Hesselstrand, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539387/ https://www.ncbi.nlm.nih.gov/pubmed/33023643 http://dx.doi.org/10.1186/s13075-020-02323-8 |
Ejemplares similares
-
Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019) -
Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis
por: Liao, Yu-Wan, et al.
Publicado: (2022) -
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
por: Hamberg, Viggo, et al.
Publicado: (2023) -
Mycophenolate mofetil in the treatment of lupus nephritis
por: Yong, Patrick FK, et al.
Publicado: (2008) -
Severe Enteropathy From Mycophenolate Mofetil
por: Jehangir, Asad, et al.
Publicado: (2016)